A single center, open-label, dose-escalating, Phase I study to evaluate the safety of GX-188E administered by electroporation (EP) in DNA-based therapeutic vaccine for patients with Cervical Intraepithelial Neoplasia grade 3 (CIN 3)
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2014
At a glance
- Drugs GX 188E (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
- Sponsors Genexine
- 10 Mar 2014 Status changed from recruiting to completed, as per Korean Clinical Trials Register record.
- 13 Feb 2013 New source identified and integrated (KCT0000586: Clinical Research Information Service (CriS) - Republic of Korea).
- 12 Nov 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History